Perspective on biotech

Blue Latitude Health|14th September 2017

Biotech companies operate in highly complex markets with extremely challenging regulatory constraints. As a creative marketing consultancy we are well positioned to cut through this noise and tackle challenges from all angles, offering leading strategic and creative solutions. 

Ahead of our upcoming report into strategic challenges and opportunities in the sector, we have been speaking to biotech experts to find out their perspective on the state of the industry. 

Here we explore some of their enlightening insights and reveal how the definition of biotech is changing as big pharma turns its research and development to biological therapies. 

Find out about: 

  • The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques
  • How to define a biotech company – is the current definition still valid?
  • Shaping the future of healthcare – solving four common challenges facing biotech companies today.

 

Empowered patients: shaking the foundations of healthcare

Blue Latitude Health|16th August 2019

Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to make a more accurate treatment decision. Here we discuss the barriers, opportunities and potential outcomes of the precision medicine era in healthcare.

read more

A uniquely English genomic medicine service

Natasha Cowan|26th July 2019

The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist and Director of Public Health at Genomics England, to find out how the NHS is achieving this goal.

read more

Diagnosing the lag in neuropsychiatric treatments

Sana Rahim|16th July 2019

The number of mental health research programmes in larger drug firms has shrunk by 70% in the past decade. Blue Latitude Health Senior Associate Consultant Sana Rahim explores this drop in investment and explains why developing a market-orientated model is vital for making progress.

 

read more